Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
Robert B. Laprairie, Amina M. Bagher, Michael E. Kelly, et al.
British Journal of Pharmacology (2015) Vol. 172, Iss. 20, pp. 4790-4805
Open Access | Times Cited: 862

Showing 26-50 of 862 citing articles:

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
María S. García‐Gutiérrez, Francisco Navarrete, Ani Gasparyan, et al.
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 210
Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC
Tomáš Hložek, Libor Uttl, L. Kadeřábek, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 12, pp. 1223-1237
Closed Access | Times Cited: 206
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
Tim Bakas, P.S. van Nieuwenhuijzen, S.O. Devenish, et al.
Pharmacological Research (2017) Vol. 119, pp. 358-370
Closed Access | Times Cited: 204
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, et al.
Neuropsychopharmacology (2017) Vol. 43, Iss. 1, pp. 142-154
Open Access | Times Cited: 204
Diversity of molecular targets and signaling pathways for CBD
Douglas Lamounier de Almeida, Lakshmi A. Devi
Pharmacology Research & Perspectives (2020) Vol. 8, Iss. 6
Open Access | Times Cited: 192
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review
Abigail M. Freeman, Kat Petrilli, Rachel Lees, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 107, pp. 696-712
Open Access | Times Cited: 181
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Jiangling Peng, Mingjie Fan, Chelsea An, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 439-456
Open Access | Times Cited: 177
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials
Emma Fisher, Andrew Moore, Alexandra E. Fogarty, et al.
Pain (2020) Vol. 162, Iss. 1, pp. S45-S66
Open Access | Times Cited: 168
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects
Nadia Solowij, Samantha J. Broyd, Lisa‐Marie Greenwood, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 269, Iss. 1, pp. 17-35
Open Access | Times Cited: 161
Cannabinoids and Cannabinoid Receptors: The Story so Far
Fred Shahbazi, Victoria Grandi, Abhinandan Banerjee, et al.
iScience (2020) Vol. 23, Iss. 7, pp. 101301-101301
Open Access | Times Cited: 160
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
Joana Gonçalves, Tiago Rosado, Sofia Soares, et al.
Medicines (2019) Vol. 6, Iss. 1, pp. 31-31
Open Access | Times Cited: 159
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products
Dongchen An, Steve Peigneur, Louise Antonia Hendrickx, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5064-5064
Open Access | Times Cited: 159
Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials
Christian Larsen, Jorida Shahinas
Journal of Clinical Medicine Research (2020) Vol. 12, Iss. 3, pp. 129-141
Open Access | Times Cited: 148
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Ayat Zagzoog, Kawthar A. Mohamed, Hye Ji J. Kim, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 144
Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
Vicente Martı́nez, Amaia Iriondo‐DeHond, Francesca Borrelli, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3067-3067
Open Access | Times Cited: 142
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages
Seegehalli M. Anil, Nurit Shalev, A. C. Vinayaka, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 126
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Elizabeth M. Burnette, Steven J. Nieto, Erica N. Grodin, et al.
Drugs (2022) Vol. 82, Iss. 3, pp. 251-274
Open Access | Times Cited: 108
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis
Reda Ben Mrid, Najat Bouchmaa, Hassan Ainani, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113126-113126
Open Access | Times Cited: 85
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 83
Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation
Dalia M. Kopustinskienė, Rūta Masteiková, Robertas Lažauskas, et al.
Antioxidants (2022) Vol. 11, Iss. 4, pp. 660-660
Open Access | Times Cited: 78
The Polypharmacological Effects of Cannabidiol
Jorge Iván Castillo-Arellano, Ana Canseco-Alba, Stephen J. Cutler, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3271-3271
Open Access | Times Cited: 70
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Thian‐Sze Wong, Guangzhi Li, Shiliang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 60

Scroll to top